Clinical Trials · NCT03273712
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- University of Iowa
- Enrollment
- 39
- Start date
- Sep 2017
- Locations
- 1 site, United States
- Primary endpoint
- Frequency of Tumor Response at 9 Months After Last Treatment